Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SB-509: Completed Phase II enrollment

SGMO completed enrollment of 102 patients with mild to moderate

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE